Next Article in Journal
Urothelial Bladder Carcinomas with High Tumor Mutation Burden Have a Better Prognosis and Targetable Molecular Defects beyond Immunotherapies
Previous Article in Journal
The Real-World Experience of the Biosimilar (Grastofil®) to the Reference Biologic (Neupogen®) in Breast Cancer and Lymphoma: A Canadian Single-Centre Retrospective Study
 
 
Article

Article Versions Notes

Curr. Oncol. 2022, 29(3), 1370-1389; https://doi.org/10.3390/curroncol29030116
Action Date Notes Link
article xml file uploaded 23 February 2022 12:33 CET Original file -
article xml uploaded. 23 February 2022 12:33 CET Update https://www.mdpi.com/1718-7729/29/3/116/xml
article pdf uploaded. 23 February 2022 12:33 CET Version of Record https://www.mdpi.com/1718-7729/29/3/116/pdf
article html file updated 23 February 2022 12:34 CET Original file -
article html file updated 1 August 2022 02:17 CEST Update https://www.mdpi.com/1718-7729/29/3/116/html
Back to TopTop